Lineage Cell Therapeutics, Inc. Impairment of Long-Lived Assets Held-for-use
Lineage Cell Therapeutics, Inc. (LCTX) reported Impairment of Long-Lived Assets Held-for-use of $1.00 thousand for the 12-month period ending 2015-12-31, per its 10-K filed 2016-03-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2016-03-15
- Lineage Cell Therapeutics, Inc. impairment of long-lived assets held-for-use for the quarter ending 2015-12-31 was $1.00K.
- Lineage Cell Therapeutics, Inc. impairment of long-lived assets held-for-use for the quarter ending 2015-09-30 was $0.00.
- Lineage Cell Therapeutics, Inc. impairment of long-lived assets held-for-use for the quarter ending 2015-06-30 was $0.00, a 100.00% decline year-over-year.
- Lineage Cell Therapeutics, Inc. impairment of long-lived assets held-for-use for the quarter ending 2015-03-31 was $0.00, a 100.00% decline year-over-year.
- Lineage Cell Therapeutics, Inc. impairment of long-lived assets held-for-use for fiscal 2015 was $1.00K, a 88.89% decline from fiscal 2014.
- Lineage Cell Therapeutics, Inc. impairment of long-lived assets held-for-use for fiscal 2014 was $9.00K.
- Lineage Cell Therapeutics, Inc. impairment of long-lived assets held-for-use for fiscal 2013 was -$5.00K, a 125.41% decline from fiscal 2012.
- Lineage Cell Therapeutics, Inc. impairment of long-lived assets held-for-use for fiscal 2012 was $19.68K, a 206.75% increase from fiscal 2011.
| Period end | Impairment of Long-Lived Assets Held-for-use 3 month | Impairment of Long-Lived Assets Held-for-use 3 month as first filed | Impairment of Long-Lived Assets Held-for-use 6 month | Impairment of Long-Lived Assets Held-for-use 6 month as first filed | Impairment of Long-Lived Assets Held-for-use 9 month | Impairment of Long-Lived Assets Held-for-use 9 month as first filed | Impairment of Long-Lived Assets Held-for-use 12 month | Impairment of Long-Lived Assets Held-for-use 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2015-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $1.00K derived: sum of 2 quarters · filed 2016-03-15 | $1.00K derived: sum of 3 quarters · filed 2016-03-15 | $1.00K 10-K · filed 2016-03-15 | ||||
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $0.00 derived: sum of 2 quarters · filed 2015-11-09 | $0.00 10-Q · filed 2015-11-09 | $0.00 derived: sum of 4 quarters · filed 2016-03-15 | ||||
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $0.00 10-Q · filed 2015-08-10 | $0.00 derived: sum of 3 quarters · filed 2016-03-15 | -$12.00K derived: sum of 4 quarters · filed 2016-03-15 | ||||
| 2015-03-31 | $0.00 10-Q · filed 2015-05-08 | $0.00 derived: sum of 2 quarters · filed 2016-03-15 | -$12.00K derived: sum of 3 quarters · filed 2016-03-15 | $424.00 derived: sum of 4 quarters · filed 2016-03-15 | ||||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | -$12.00K derived: sum of 2 quarters · filed 2016-03-15 | $424.00 derived: sum of 3 quarters · filed 2016-03-15 | $9.00K 10-K · filed 2016-03-15 | $9.32K 10-K · filed 2015-03-11 | |||
| 2014-09-30 | -$12.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $424.00 derived: sum of 2 quarters · filed 2015-11-09 | $9.00K 10-Q · filed 2015-11-09 | $8.71K 10-Q · filed 2014-11-07 | $9.12K derived: sum of 4 quarters · filed 2016-03-15 | |||
| 2014-06-30 | $12.42K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $21.00K 10-Q · filed 2015-08-10 | $21.03K 10-Q · filed 2014-08-11 | $21.12K derived: sum of 3 quarters · filed 2016-03-15 | $15.29K derived: sum of 4 quarters · filed 2016-03-15 | |||
| 2014-03-31 | $8.58K 10-Q · filed 2015-05-08 | $8.70K derived: sum of 2 quarters · filed 2016-03-15 | $2.87K derived: sum of 3 quarters · filed 2016-03-15 | $2.05K derived: sum of 4 quarters · filed 2016-03-15 | ||||
| 2013-12-31 | $120.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | -$5.71K derived: sum of 2 quarters · filed 2016-03-15 | -$6.52K derived: sum of 3 quarters · filed 2016-03-15 | -$5.00K 10-K · filed 2016-03-15 | -$5.12K 10-K · filed 2014-03-17 | |||
| 2013-09-30 | -$5.83K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | -$6.64K derived: sum of 2 quarters · filed 2014-11-07 | -$5.12K 10-Q · filed 2014-11-07 | $9.56K derived: sum of 4 quarters · filed 2015-03-11 | ||||
| 2013-06-30 | -$813.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $710.00 10-Q · filed 2014-08-11 | $15.39K derived: sum of 3 quarters · filed 2015-03-11 | $16.84K derived: sum of 4 quarters · filed 2015-03-11 | ||||
| 2013-03-31 | $1.52K 10-Q · filed 2014-05-12 | $1.52K 10-Q · filed 2013-05-10 | $16.21K derived: sum of 2 quarters · filed 2015-03-11 | $17.66K derived: sum of 3 quarters · filed 2015-03-11 | $21.20K derived: sum of 4 quarters · filed 2015-03-11 | |||
| 2012-12-31 | $14.68K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-11 | $16.14K derived: sum of 2 quarters · filed 2015-03-11 | $19.68K derived: sum of 3 quarters · filed 2015-03-11 | $19.68K 10-K · filed 2015-03-11 | ||||
| 2012-09-30 | $1.45K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $5.00K derived: sum of 2 quarters · filed 2013-11-12 | $5.00K 10-Q · filed 2013-11-12 | $4.91K derived: sum of 4 quarters · filed 2014-03-17 | ||||
| 2012-06-30 | $3.55K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | $3.55K 10-Q · filed 2013-08-09 | $3.46K derived: sum of 3 quarters · filed 2014-03-17 | |||||
| 2012-03-31 | $0.00 10-Q · filed 2013-05-10 | -$86.00 derived: sum of 2 quarters · filed 2014-03-17 | ||||||
| 2011-12-31 | -$86.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-17 | $6.42K 10-K · filed 2014-03-17 | ||||||
| 2011-09-30 | $6.50K 10-Q · filed 2011-11-08 | |||||||
| 2010-12-31 | $993.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | $993.00 10-K · filed 2013-03-18 | ||||||
| 2010-09-30 | $0.00 10-Q · filed 2011-11-08 | |||||||
| 2009-12-31 | $1.16K 10-K · filed 2012-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |